ARCHIVES

Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: MDA Treats Only 9% Of Texas Cancer Patients; Clinical Director Search Narrows To Three

March 12, 1976

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

January 6, 1989

Also in this 8-page issue: Intel Chairman Andrew Grove slams NCI director and cancer program for “wishful dreams” and “chemo speeches,” recommends moratorium on funding for cancer research.

May 14, 2004

No Benefit To Kidney Removal For Elderly With Kidney Cancer

May 28, 2010

NIH Policy On Diversity In Sponsored Meetings

June 16, 1995

Washington Braces For Oncologists; It’s The Spring Meetings

May 4, 1990